Business opportunities Photo by Floriane Vita on Unsplash)

Meet us at Sachs NCIF Forum: 7-9 Jul. 2020

Meet us at the Sachs Digital Novel Coronavirus Investment Forum 2020

Accelerate neutralizing antibody development with single cell analysis to protect vulnerable immunocompromised individuals

Proteona Antibody Protection GmbH will be presenting its coronavirus neutralizing antibody development and investment opportunities at the Sachs-NCIF forum, taking place virtually on the 7th-9th of July 2020.

Watch our presentation at the Emerging Technologies companies showcase, which will be available on the event portal. The showcases are supported by EIT Health e.V. to highlight investment opportunities in healcare innovations.

Proteona Antibody Protection GmbH is using single cell sequencing technology to accelerate neutralizing antibody development against coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

The Digital Novel Coronavirus Investment Forum (NCIF) focuses on the healthcare revolution as a response to the pandemic. Featuring high-level plenary sessions and global company showcases, it provides a platform for discussing the emerging innovative solutions and future opportunities.

Dr Andreas Schmidt, the CEO of Proteona Antibody Protection GmbH, will be available during the event for further discussion.

Schedule a meeting

NCIF forum event website

For media queries, please contact:

Dr Andreas Schmidt
Proteona Antibody Protection GmbH

About Proteona Antibody Protection GmbH

Proteona Antibody Protection GmbH is a biomedical company operating at the forefront of the fight against COVID-19 using single cell sequencing technology to discover neutralizing antibodies. Proteona’s vision is to accelerate treatment development for the most vulnerable, immunocompromised patients. Its parent company, Proteona, is already active in Singapore and Germany, where it provides single-cell multi-omics data for researchers, clinicians and pharma companies for drug discovery and for treatment optimization for blood cancer patients.